Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan

BackgroundEfgartigimod, a neonatal Fc receptor blocker, has received regulatory approval for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Japan in December 2024.AimsTo investigate the effectiveness and safety of efgartigimod in real-world clinical setting imme...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Tatsuya Imai, Kenichi Irie, Shinichiro Mori, Tomoaki Hoshino, Toshihiro Ide, Takahisa Tateishi
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-03-01
Schriftenreihe:	Frontiers in Neurology
Schlagworte:	case series study chronic inflammatory demyelinating polyradiculoneuropathy CIDP variant efgartigimod Japan neonatal Fc receptor blocker
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fneur.2026.1748826/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!